08/23/2017

NCCN has published updates to the NCCN Templates® for Hodgkin Lymphoma and B-Cell Lymphomas. 

NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates^®) for Hodgkin Lymphoma and B-Cell Lymphomas. 

• The agent name brentuximab has been updated to include the antibody-drug conjugate “vedotin” across all disease sites. The new name will read “Brentuximab vedotin.” The following templates have been updated to reflect this change:
  • HDL31 – Brentuximab vedotin
  • DBL47 – Brentuximab vedotin
• Emetic risk for brentuximab vedotin has been updated from Minimal to Low across all disease sites to reflect the NCCN Guidelines for Antiemesis, Version 2.2017. The following templates have been updated to reflect this change:
  • HDL31 – Brentuximab vedotin
  • DBL47 – Brentuximab vedotin